Drugs / MSB11022
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04018599 | Jul 2019 → Mar 2020 | Crohn disease, ankylosing spondylitis, hidradenitis suppurativa, polyarticular juvenile idiopathic arthritis +4 | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03014947 | May → Dec 2014 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03052322 | Jan 2017 → May 2018 | rheumatoid arthritis | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02660580 | Feb → Dec 2016 | psoriasis | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSB11022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02660580 ↗ |
| Route | Subcutaneous | “Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and...” NCT02660580 ↗ |